COMP <GO>
QGEN vs MRK // FORWARD P/E MULTIPLE
Qiagen N.V. (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: QGEN 5
— MRK 10
▲ FORWARD P/E MULTIPLE LEADER: MRK
LAST: $50.22 (-0.24%) • MKT CAP: $10.37B
forward-pe
22.7x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
forward-pe
18.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (QGEN VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | QGEN | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 62.20% | 74.80% | -12.60 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.00% | 20.70% | -12.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 17.6x | 15.3x | +2.30 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 4.37% | 3.42% | +0.95 | QGEN | /fcf-yield <GO> |
| Operating Margin | 22.30% | 34.30% | -12.00 | MRK | /operating-margins <GO> |
| Net Profit Margin | 20.30% | 28.10% | -7.80 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 5.70% | 1.30% | +4.40 | QGEN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.52% | 2.26% | -1.74 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.54 | 5.19 | -1.65 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | QGEN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.60% | +0.10 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 71.9 | 56.9 | +15.07 | QGEN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 0.92 | +0.03 | QGEN | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 22.7x | 18.4x | +4.30 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.37B | $361.02B | -$350.65B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | QGEN REV | MRK REV | QGEN GROSS % | MRK GROSS % | QGEN FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.09B | $65.01B | 62.2% | 74.8% | $453.3M | $12.36B |
| FY 2024 | $1.98B | $64.17B | 48.9% | 76.3% | $506.4M | $18.10B |
| FY 2023 | $1.97B | $60.12B | 44.0% | 44.0% | $371.0M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
QGEN // BETA 0.95
MRK // BETA 0.92